Division of Thoracic Oncology, Shizuoka Cancer Center, Nagaizumi, Japan
Division of Thoracic Oncology, Shizuoka Cancer Center, Nagaizumi, Japan.
In Vivo. 2019 Nov-Dec;33(6):2229-2234. doi: 10.21873/invivo.11727.
BACKGROUND/AIM: To evaluate treatment efficacy of cisplatin, etoposide, and irinotecan combined therapy (PEI), platinum-rechallenge chemotherapy (Pt-Re) and amrubicin monotherapy (AMR) for patients with sensitive relapsed small cell lung cancer (SCLC).
We defined sensitive relapse as treatment-free interval (TFI) ≥90 days. We retrospectively collected patients' data from medical records between September 2002 and December 2016. Patients with sensitive relapsed SCLC who received second-line chemotherapy were separated into those treated with PEI, with Pt-Re, or with AMR.
Seventy-one patients (16 PEI group, 27 Pt-Re group, and 28 AMR group) were assessable for efficacy. No significant differences in patient characteristics were found among the three groups. The median overall survival (MST) was 29.3 months in the PEI group, 24.6 months in the Pt-Re group, and 20.6 months in the AMR group (p=0.042).
A significant difference was observed in the overall survival of patients treated with PEI, Pt-Re and AMR and the MST of PEI was the longest.
背景/目的：评估顺铂、依托泊苷和伊立替康联合治疗（PEI）、铂类药物再挑战化疗（Pt-Re）和氨柔比星单药治疗（AMR）对敏感复发性小细胞肺癌（SCLC）患者的治疗效果。
我们将治疗无进展期（TFI）≥90 天定义为敏感复发。我们回顾性地从 2002 年 9 月至 2016 年 12 月的病历中收集了患者的数据。接受二线化疗的敏感复发性 SCLC 患者分为接受 PEI、Pt-Re 或 AMR 治疗的患者。
71 例患者（16 例 PEI 组、27 例 Pt-Re 组和 28 例 AMR 组）可评估疗效。三组患者的一般特征无显著差异。PEI 组的中位总生存期（MST）为 29.3 个月，Pt-Re 组为 24.6 个月，AMR 组为 20.6 个月（p=0.042）。
PEI、Pt-Re 和 AMR 治疗患者的总生存期存在显著差异，PEI 的 MST 最长。
